Cushing's syndrome involves symptoms such as high blood pressure, abdominal obesity, round red face, a fatty lump between the shoulders, weak muscles and bones, acne, fragile skin and others. Most Cushing's syndrome cases are caused by pituitary adenoma, and multiple endocrine neoplasia.
In terms of value, North America is expected to be the dominant regional market for Cushing’s Syndrome treatment by 2025 and is expected to expand at a CAGR of 9% over the forecast period.
In 2017, the global Cushing's Syndrome Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2018-2025.
This report focuses on the global Cushing's Syndrome Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Cushing's Syndrome Treatment development in United States, Europe and China.
The key players covered in this study
Pfizer
Novartis
Bristol-Myers Squibb
Corcept Therapeutics
HRA Pharma
Ipsen Biopharmaceuticals
...
Market segment by Type, the product can be split into
Glucocorticoid Receptor Inhibitors
Somatostatin
Ketoconazole HRA
Others
Market segment by Application, split into
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Cushing's Syndrome Treatment status, future forecast, growth opportunity, key market and key players.
To present the Cushing's Syndrome Treatment development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Cushing's Syndrome Treatment are as follows:
History Year: 2013-2017
Base Year: 2017
Estimated Year: 2018
Forecast Year 2018 to 2025
For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.